Recruiting

Peanut Consumption

Sponsor:

Henry Ford Health System

Code:

NCT07646197

Conditions

MASLD

Fatty Liver

Eligibility Criteria

Sex: All

Age: 30 - 70

Healthy Volunteers: Not accepted

Interventions

Peanut consumption

Study Details

Brief summary:

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.

  • Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
  • Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
  • Daily log to be completed for tracking peanut consumption
  • 2-day Dietary recall at baseline, during Week 6 and Week 12
  • Poat intervention Fibro scans for participants with baseline scans available

Conditions

MASLD

Fatty Liver

Study ID

NCT07646197

Start date

Jun 9, 2026

Status verified date

Jun, 2026

Completion date

Jun 9, 2028

Anticipated

Primary completion date

Apr 6, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 30 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 30-70 years
  • do not consume peanut/peanut butter/treenut/seeds > /week
  • at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
  • Able to understand, speak, and read English
  • Mentally competent to consent

Exclusion Criteria:

  • Food allergy to peanuts or peanut-containing products
  • With alcohol use disorder (AUDIT screening)
  • Leukemia
  • Lymphoma
  • Other types of cancer
  • Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
  • Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)

Study Design

Enrollment

125 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Peanut

MASLD patients will consume 50 gm of peanut daily for 12 weeks

no intervention: Control

Regular diet

Interventions

Peanut consumption

MASLD patients will consume 50 gm of peanut daily for 12 weeks

Primary outcome measure

  • Hepatic Markers [ Time Frame: Baseline to post-intervention (12 weeks) ]

Central Contacts and Locations

Central contacts

Locations

Henry Ford Health System

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Menghua Tao, Ph.D.

3138768471mtao1@hfhs.org

More Information

Sponsor

Henry Ford Health System

Last update posted

Aug 6, 2026

Last verified

Jun, 2026

Keywords

  • fatty liver
  • masld
  • peanut
  • hepatic
  • intervention
  • gut microbe

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Henry Ford Health System on 2026-08-06.